IL6 and cancer: Accordingly, combining IL-6 blockades with genotoxic agents not only impairs the abilities of cancer cells to evade genotoxic effects but may also alleviate the induction of the pro-tumorigenic M2-like macrophages in the tumor microenvironment under genotoxic conditions, thereby contributing to improving treatment outcomes.